IDHIPLI (U.S. Trademark Serial Number 87143228) is a United States trademark of Celgene Corporation. The goods and services include: Pharmaceutical preparations for use in the treatment of beta thalassemia and myelodysplastic syndromes, autoinflammatory disease, autoimmune disease, blood disease, cancer, arthritis, musculoskeletal and skin diseases in the fields of oncology, immunology and inflammation; pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system . The correspondent is CAMILLE M. MILLER of COZEN O’CONNOR.

This trademark was filed on August 18, 2016 as United States Trademark Application Serial Number 87143228. The trademark application was registered on July 04, 2017 as U.S. Trademark Registration 5235422.

Trademark PTO Status History

July 04, 2022 – COURTESY REMINDER – SEC. 8 (6-YR) E-MAILED

July 04, 2017 – REGISTERED-PRINCIPAL REGISTER

June 01, 2017 – 1(B) BASIS DELETED; PROCEED TO REGISTRATION

May 02, 2017 – NOTICE OF ALLOWANCE CANCELLED

May 19, 2017 – CASE ASSIGNED TO INTENT TO USE PARALEGAL

May 02, 2017 – TEAS POST PUBLICATION AMENDMENT RECEIVED

May 02, 2017 – NOA E-MAILED – SOU REQUIRED FROM APPLICANT

March 07, 2017 – OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

View full trademark status information at USPTO

Ownership History

Celgene Corporation

Celgene Corporation

Celgene Corporation

View documents on file at USPTO

File a Trademark or Get Help With Trademark Law

Select IP monitors top trademarks which have been allowed and granted worldwide. We are experts in trademark law. If you are interested in connecting with an IP law attorney or patent law attorney, please contact us via the contact form.